

**The Ottawa Statement, Part One:  
Principles for international registration of protocol information and results from  
human trials of health-related interventions**

Karmela Krleža-Jerić (MD, DSc),<sup>1</sup> An-Wen Chan (MD, DPhil),<sup>1,2</sup> Kay Dickersin (MA, PhD),<sup>3</sup>  
Ida Sim (MD, PhD),<sup>4</sup> Jeremy Grimshaw (MB, PhD),<sup>5</sup> and Christian Gluud (MD, D.MSc),<sup>6</sup> for  
the Ottawa Group<sup>7</sup>

<sup>1</sup> Randomized Controlled Trials Unit, Canadian Institutes of Health Research, Ottawa, Canada (This does not imply CIHR's official endorsement of the Ottawa Statement)

<sup>2</sup> Department of Medicine, University of Toronto, Canada

<sup>3</sup> Department of Community Health, Brown University, Providence, USA

<sup>4</sup> Department of Medicine, University of California, San Francisco, USA

<sup>5</sup> Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Canada

<sup>6</sup> The European Clinical Research Infrastructures Network; The Copenhagen Trial Unit, Centre for Clinical Intervention Research; & The Cochrane Hepato-Biliary Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>7</sup> Members listed at [www.bmj.com/](http://www.bmj.com/) \_\_\_\_\_

Corresponding author:

Karmela Krleža-Jerić, M.D., M.Sc., D.Sc.

Randomised Controlled Trials / Essais randomisés et contrôlés

Canadian Institutes of Health Research / Instituts de recherche en santé du Canada

Ph: (613) 957-6130

email: [kkrleza-jeric@cihr-irsc.gc.ca](mailto:kkrleza-jeric@cihr-irsc.gc.ca)

## **A. Objective**

The Ottawa Statement aims to establish internationally recognised principles for trial registration (Part 1) as well as their proposed operationalisation (Part 2).<sup>1</sup>

## **B. Definitions**

'Trial' refers to a prospective controlled or uncontrolled research study evaluating the effects of one or more health-related interventions assigned to human participants. For example, a trial may investigate interventions related to one or more of the following: prevention, health promotion, screening, diagnosis, treatment, rehabilitation, or organisation and financing of care.

'Intervention' refers to a deliberate act applied to an individual or group of individuals. Health-related interventions include but are not limited to the use of pharmaceuticals, biological products, surgery, procedures, radiation, devices, education, counselling, behaviour change, complementary health modalities, and management or economic policies.

'Registration' of a trial involves the assignment of a unique identification number; the recording and public release of protocol information; as well as the recording and public release of trial results.

'Protocol' refers to a document written before participant enrolment to describe the objectives, methodology, statistical analyses, organisation, and administrative details of a trial.

'International' refers to the applicability of the principles presented in this document to trials conducted in any country or countries worldwide.

'Sponsor' is defined as an individual, company, institution, or organisation that takes responsibility for the initiation, management, and/or financing of a trial. The sponsor does not actually conduct the investigation unless the sponsor is an investigator-sponsor.

'Principal investigator' is defined as the person responsible for the overall conduct of the trial

---

<sup>1</sup> The operationalisation of these principles is under development and will be presented in a separate document as Part 2 of the Ottawa Statement.

## **C. Rationale for international trial registration**

### **C.1. Ethical rationale**

C.1.1. Above all, international trial registration is necessary to fulfill ethical obligations to research participants. When members of the public agree to participate in trials, it is on the understanding that they are contributing to the global body of health-related knowledge. It is thus unethical to conduct human research without ensuring that valid descriptions of the study and its findings are publicly available.

C.1.2. Potential trial participants, care providers, researchers, institutional review boards/independent ethics committees (IRB/IECs), and sponsors should have access to valid information about trials that have been previously performed.

C.1.3. Potential trial participants, care providers, researchers, IRB/IECs, and sponsors should have access to valid information about trials that are currently open for enrolment.

C.1.4. The availability of unbiased information about all initiated trials contributes to global open access to knowledge, which constitutes a public good.

### **C.2. Scientific rationale**

Public access to trial protocol information (as approved by the IRB/IEC) and results will help to:

C.2.1. Minimise known risks and potential harm arising from unnecessary exposure to previously tested interventions;

C.2.2. Accelerate research by making knowledge available about prior experiences with interventions;

C.2.3. Identify and deter unnecessary duplication of research and publications;

C.2.4. Identify and deter selective reporting of research (reporting biases);

C.2.5. Provide a means of comparing the original protocol upon which ethics approval was based with the study as it was carried out;

C.2.6. Enhance collaboration among researchers by informing them of ongoing trials.

## **D. Principles regarding the scope and nature of international trial registration**

### **D.1. Types of trials to be registered**

Protocol information (D.4) and results (D.5) from all trials related to health or healthcare – regardless of topic, design, outcomes, or market status of interventions examined – should be registered and publicly available.

### **D.2. Elements of registration**

Registration of each trial comprises three distinct parts: obtaining an internationally unique identification number (D.3), registering the original protocol approved by the IRB/IEC along with subsequent amendments (D.4), and registering the trial results (D.5). A general timeline for registration is shown in the Figure.

### **D.3. Principles relating to unique identification number (Unique ID)**

#### **D.3.1. Assignment of Unique ID**

Every trial should have a Unique ID assigned by a single international source prior to participant enrolment. The Unique ID should be verifiable and have built-in error-detecting logic.

#### **D.3.2. Application of Unique ID**

The Unique ID should appear on all trial documentation, including the consent form given to participants as well as subsequent presentations and publications.

### **D.4. Principles relating to protocol registration**

#### **D.4.1. Definition of protocol information to be registered**

Protocol information in the register should consist of (1) a minimum set of standardised, structured, key items from the protocol approved by the IRB/IEC (“minimum protocol items”); (2) the consent forms approved by the IRB/IEC; and (3) any subsequent protocol amendments. Protocol information from each of these components should be irreversibly recorded and dated at the time of submission to the register (D.4.2). The minimum protocol items registered should be sufficient to enable critical appraisal of trial methodology and statistical analyses. Furthermore, the full protocol as approved by the IRB/IEC, and the data collection forms, should be available in the public domain to enable the interpretation of trial findings.

#### **D.4.2. Timing of protocol registration**

Registration of the minimum protocol items and the consent forms should occur prior to enrolment of trial participants. Amendments to the registered protocol information should be dated and registered as they occur.

#### **D.4.3. Timing of public access to registered protocol information**

The public should have cost-free access to the Unique ID, minimum protocol items, and consent forms prior to participant enrolment. Registered amendments should be made publicly available as they occur. The full protocol as approved by the IRB/IEC, and the data collection forms, should be made publicly available as soon as possible and no later than

the date of completion of data analysis.

## **D.5. Principles relating to registration of trial results**

### **D.5.1. Definition of trial results to be registered**

At a minimum, results for outcomes and analyses specified in the protocol (as approved by the IRB/IEC), as well as data on harms, should be registered regardless of whether or not they are published. If a trial is terminated prematurely, any available results should be registered along with the reason for termination.

The summary results recorded for each outcome should be sufficient for valid interpretation, and should not enable identification of any individual trial participant to the public.

Full citations to trial publications should be registered as they become available. However, listing of study publications alone does not constitute adequate registration of results.

### **D.5.2. Timing of registration of trial results**

Trial results should be registered once the analyses are completed and verified.

### **D.5.3. Timing of public access to registered results**

Investigators should have sufficient time to publish their findings in a peer-reviewed electronic or print forum before the registered results are released for public, free-of-charge access. Timely public access to results should ultimately be assured regardless of their publication status.

## **D.6. Organisation and language of registries**

The source assigning the Unique ID can exist separately from the register or registers that contain protocol information and trial results. However, all three components (Unique ID, protocol information, trial results) must be cross-referenced.

To facilitate efficient searching, multiple national or regional registers should be linked. Furthermore, registered information must be presented at least in English and also preferably in the major language(s) of the region where the main study site is located.

## **E. Responsibilities of involved parties**

### **E.1. Sponsors**

The sponsor(s) of the trial has ultimate responsibility for obtaining the Unique ID (D.3) as well as for registering the protocol information (D.4) and results (D.5). The sponsor should also ensure that the full protocol as approved by the IRB/IEC, and the data collection forms, are made publicly available. When there are multiple sponsors, each sponsor is individually responsible for ensuring that these tasks are fulfilled.

### **E.2. Investigators**

The principal investigator has a responsibility to ensure that the sponsor(s) obtains a

Unique ID and registers his or her contact information, the protocol information (D.4), and the trial results (D.5). Investigators also have the responsibility to perform analyses in a timely fashion and to submit the findings for publication in a peer-reviewed electronic or print forum.

### **E.3. Institutional review boards/independent ethics committees**

IRBs/IECs have a responsibility to ensure that approved trials have a Unique ID; that minimum protocol items and consent forms, as approved by the board, are registered prior to participant enrolment; and that subsequent protocol amendments are reported and registered. They are also responsible for ensuring that the Unique ID appears on the consent form. Furthermore, they are responsible for encouraging the publication of trial results in a peer-reviewed electronic or print forum. When a trial receives approval from multiple IRB/IECs, each board is responsible for ensuring that these tasks are fulfilled.

### **E.4. Journal editors**

Journal editors have a responsibility to promote trial registration by requiring that any trial being considered for publication has a Unique ID, and to include the Unique ID in any resulting publication.

### **E.5. Policing and sanctions**

Trial registration should be a legal requirement, with enforcement of meaningful sanctions against those found to be in violation.




Figure. General time-line for process of trial registration

## THE OTTAWA GROUP

The members of the Ottawa Group listed below have formally endorsed Part 1 of the Ottawa Statement:

### GROUP SIGNATORIES

Various organisations that endorsed the Ottawa Statement are listed alphabetically below, along with the individual who signed on their behalf (in parentheses).

1. **Cochrane Consumer Network - CCNet**, Australia (Janet Wale)
2. **Current Trials Ltd** - [www.controlled-trials.com/isrctn](http://www.controlled-trials.com/isrctn) (Anne Greenwood)
3. **Dutch Cochrane Centre** (Rob Scholten)
4. **European Clinical Research Infrastructure Network** [www.eclin.org](http://www.eclin.org), (Christian Gluud)  
As of January 2005, ECRIN covers six European countries representing 112 centres conducting 1500 clinical studies. Each national network and the European Forum for Good Clinical Practice are represented in ECRIN as follows:
  - a) Danish Clinical Research Infrastructures Network (Christian Gluud)
  - b) French Clinical Research Centre's Network (Jacques Demotes-Mainard)
    1. Methods in Clinical Research Unit, Centre Hospitalier Universitaire, Toulouse, France (Thierry Lang)
  - c) French Clinical Trial Unit Network (Jean-Pierre Pignon)
  - d) German Network of Coordination Centres for Clinical Trials (Christian Ohmann)
  - e) Italian Clinical Research Infrastructures Network (Nicola Fabris)
  - f) Mario Negri Institute, Italy (Silvio Garattini)
  - g) Spanish Clinical Trials Network (Xavier Carné)
  - h) Swedish Clinical Research Infrastructures Network (Pierre Lafolie)
  - i) European Forum for Good Clinical Practice (Francis P. Crawley)

### 5. Research-based Education and Quality Improvement - ReBEQI

(Andy Oxman)

ReBEQI ([www.rebeqi.org](http://www.rebeqi.org)) is a European Union funded project that brings together seven of Europe's leading quality improvement research groups with around 25 active researchers. Its objectives include the prospective registration of quality improvement trials and promoting publication of protocols. The centres and co-ordinators of the project are as follows:

- a) Santé Publique et Informatique Médicale (SPIM), Faculté de Médecine Broussais - Hôtel Dieu, Paris, France (Pierre Durieux)
- b) Unit of Clinical Governance, Agenzia Sanitaria Regionale (Regional Health Care Agency) of Emilia-Romagna, Bologna, Italy (Roberto Grilli)
- c) Center for the Evaluation of Effectiveness of Health Care (Ce.V.E.A.S.), Modena, Italy (Alessandro Liberati)
- d) Centre for Quality of Care Research, University of Nijmegen, The Netherlands (Richard Grol)
- e) Norwegian Health Services Research Centre, Oslo, Norway (Andy Oxman)
- f) Division of International Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden (Cecilia Lunborg)

g) Centre for Health Services Research, University of Newcastle, Newcastle, United Kingdom (Martin Eccles)

**6. Research Institute of the Children's Hospital of Eastern Ontario - [www.cheori.org](http://www.cheori.org)**  
(David Moher)

**7. Trout Research and Education Centre, [www.nsite.ca](http://www.nsite.ca)** (David Sackett)

### **INDIVIDUAL SIGNATORIES**

Individuals marked with \* are also represented by organisations, projects, or groups listed above. Except when specifically indicated, the individuals below signed on their own behalf and thus their signatures do not imply official endorsements of the Ottawa Statement by their respective groups, organisations, or institutions.

Alonso, Pedro L. \*  
International Health Center  
Hospital Clínic, University of Barcelona  
Barcelona, Spain

Altman, Douglas  
Centre for Statistics in Medicine  
Oxford, UK

Andersen, Ove\*  
Clinical Research Unit, Hvidovre Hospital  
Hvidovre, Denmark

Barrowman, Nick \*  
Chalmers Research Group  
Children's Hospital of Eastern Ontario Research Institute  
Ottawa, Canada

Benichou, Jacques \*  
Clinical Research Unit, Rouen University Hospital  
Rouen, France

Berger, Virginie \*  
Clinical Research Unit, Centre Paul Papin  
Angers, France

Burnand, Bernard  
Healthcare Evaluation Unit (IUMS), Hospices (CHUV)  
Lausanne, Switzerland

Busgeeth, Karishma  
Cochrane HIV/AIDS Trials Register and the South African Cochrane Centre  
Medical Research Council (MRC)  
Cape Town, South Africa

Carné, Xavier \*  
Clinical Pharmacology Unit  
Hospital Clínic  
Barcelona, Spain

Carrat, Fabrice \*  
Epidemiology of Infectious Diseases Unit  
Institut national de la santé et de la recherche médicale (INSERM)  
Paris, France

Chan, An-Wen  
Canadian Institutes of Health Research (CIHR-IRSC) and University of Toronto  
Toronto, Canada

Chauvin, Franck \*  
Loire Cancer Institute, Public Health Department  
Saint Etienne, France

Chêne, Geneviève \*  
Institut national de la santé et de la recherche médicale (INSERM)  
Bordeaux, France

Clark, Albert  
Canadian Association of Research Ethics Boards (CAREB),  
Health Sciences Research Ethics Board, Queens University  
Kingston, Canada

Collet, Jean-Paul  
McGill University and GEREQ Initiative for Clinical Research  
Montreal, Canada

Costagliola, Dominique \*  
Institut national de la santé et de la recherche médicale (INSERM)  
Paris, France

Coutu, Joyce  
United States Cochrane Center  
Brown University

Providence, USA

Demotes-Mainard, Jacques \*  
Institut national de la santé et de la recherche médicale (INSERM)  
Bordeaux, France

Dickersin, Kay  
United States Cochrane Center  
Brown University  
Providence, USA

Djulgovic, Benjamin  
H. Lee Moffitt Cancer Centre and Research Institute  
Tampa, USA

Dubois-Flynn, Genevieve  
Ethics, Canadian Institutes of Health Research (CIHR-IRSC)  
Ottawa, Canada

Durieux, Pierre \*  
Santé Publique et Informatique Médicale  
Faculté de médecine René Descartes - Paris 5  
Paris, France

Faure, Helene \*  
Current Controlled Trials Ltd - ISRCTN  
London, UK

Fergusson, Dean.  
Ottawa Health Research Institute, Clinical Epidemiology Program  
Ottawa, Canada

Flottorp, Signe \*  
Informed Choice Research Department  
Norwegian Health Services Research Centre  
Oslo, Norway

Foy, Robbie  
Newcastle University  
Newcastle, UK

Fraser, William D.  
Department of Obstetrics and Gynaecology, [Université de Montréal](#)  
Montreal, Canada

Gagnier, Joel J.  
Faculty of Medicine, University of Toronto  
Toronto, Canada

Garattini, Silvio \*  
Mario Negri Institute  
Milan, Italy

Gherzi, Davina  
NHMRC Clinical Trials Centre  
Sydney, Australia

Glatman, Elena  
US Cochrane Centre  
Brown University  
Providence, USA

Gluud, Christian \*  
The Copenhagen Trial Unit, Centre for Clinical Intervention Research; & The Cochrane  
Hepato-Biliary Group, Rigshospitalet, Copenhagen University Hospital,  
Copenhagen, Denmark

Gluud, Lise Lotte \*  
Cochrane Hepato-Biliary Group  
Copenhagen Trial Unit  
Copenhagen, Denmark

Godlee, Fiona  
BMJ Publishing Group,  
London, UK

Goodyear, Michael  
Ethics Board, Dalhousie University  
Dalhousie, Canada

Gøtzsche, Peter C.  
The Nordic Cochrane Centre  
Copenhagen, Denmark

Greenwood, Anne \*

Current Controlled Trials Ltd - ISRCTN  
London, UK

Grimshaw, Jeremy \*  
Clinical Epidemiology Program, Ottawa Health Research Institute  
Ottawa, Canada

Guiguet, Marguerite \*  
Institut national de la santé et de la recherche médicale (INSERM)  
Paris, France

Guillemin, Francis \*  
Clinical Epidemiology Centre, Institut national de la santé et de la recherche médicale  
(INSERM)  
University Hospital Marin  
Nancy, France

Hatem, Marie  
University of Montreal's site-Canadian Cochrane Network  
Université de Montréal  
Montreal, Canada

Herxheimer, Andrew  
UK Cochrane Centre  
London, UK

Jeffery, Mark  
Cancer Trials, Christchurch Hospital  
Christchurch, New Zealand

Kramar, Andrew  
Biostatistics Unit, Val d'Aurelle Regional Cancer Center  
Montpellier, France

Krleža-Jerić, Karmela  
Canadian Institutes of Health Research (CIHR-IRSC)  
Ottawa, Canada

Lang, Thierry\*  
Methods in Clinical Research Unit  
Centre Hospitalier Universitaire  
Toulouse, France

Leizorovicz, Alain

University Lyon I,  
Lyon, France

Lemmens, Trudo  
Faculties of Law and Medicine, University of Toronto  
Toronto, Canada

Liberati, Alessandro \*  
Università di Modena e Reggio Emilia  
Modena, Italy

Lippman, Abby  
McGill University  
Montreal, Canada

Marušić, Ana  
Croatian Medical Journal (CMJ), and Zagreb University School of Medicine  
Zagreb, Croatia

Mathoulin-Pelissier, Simone\*  
Clinical Epidemiology Unit , Institut Bergonié  
Bordeaux, France

McGuire, Hugh  
Trials Search Coordinator  
Cochrane Depression, Anxiety & Neurosis Group  
Kings College Institute of Psychiatry  
London, UK

Mercier, Mariette \*  
Faculty of Medicine and Pharmacy  
Besançon, France

Mišak, Aleksandra  
Canadian Medical Association Journal (CMAJ) and Croatian Medical Journal (CMJ)  
Ottawa, Canada and Zagreb, Croatia

Moher, David \*  
Research Institute, Children's Hospital of Eastern Ontario  
Ottawa, Canada

Napoli, Maryann  
Center for Medical Consumers  
CCNet, Cochrane Consumer Network

New York, USA

Ohmann, Christian\*  
Coordination Centre for Clinical Trials  
Heinrich Heine University  
Düsseldorf, Germany

O'Rourke, Keith  
Élisabeth Bruyère Research Institute and Ottawa Health Research Institute  
Ottawa, Canada

Oxman, Andy \*  
Research Based Education and Quality Improvement project (ReBEQI)  
Norwegian Health Services Research Centre  
Oslo, Norway

Pignon, Jean-Pierre \*  
French Clinical Trial Unit Network  
Service de biostatistique et d'épidémiologie  
Institut Gustave-Roussy  
Villejuif, France

Preux, Pierre-Marie \*  
Clinical Research and Biostatistic Unit  
Limoges University Hospital  
Limoges, France

Ravaud, Philippe \*  
Paris Nord Clinical Research Unit; Epidemiology, Biostatistics and Clinical Research  
Department, Bichat Hospital  
Paris, France

Rennie, Drummond  
JAMA, UCSF & US Cochrane Centre  
San Francisco, USA

Reveiz, Ludovic  
The Latinoamerican Ongoing Clinical Trials Register (Latinrec)  
Colombian Cochrane Collaboration Center – Clínica Reina Sofía.  
Bogotá, Colombia

Robinson, Karen A.  
Johns Hopkins University  
Baltimore, USA

Sackett, David \*  
Trout Research and Education Centre  
Markdale, Canada

Saginur, Raphael  
Ottawa Hospital Research Ethics Board  
Ottawa, Canada

Scherer, Roberta W.  
University of Maryland School of Medicine  
Department of Epidemiology and Preventive Medicine  
Baltimore, USA

Schmid, Isabelle  
Randomized Controlled Trials, Canadian Institutes of Health Research (CIHR-IRSC)  
Ottawa, Canada

Scholten, Rob J.P.M \*  
Dutch Cochrane Centre.  
Amsterdam, Netherlands

Sim, Ida  
University of California at San Francisco  
San Francisco, USA

Simes, John  
Clinical Trials Centre,  
University of Sydney  
Sydney, Australia

Soubeyran, Pierre\*  
Clinical Research Unit, Institut Bergonié  
Bordeaux, France

Trelle, Sven  
Cochrane Haematological Malignancies Group (CHMG), University Hospital Cologne  
Cologne, Germany

Trilla, Antoni \*  
Assessment, Prevention and Support Unit (UASP)  
Hospital Clinic, University of Barcelona  
Barcelona, Spain

Volmink, Jimmy  
Faculty of Health Sciences, University of Cape Town & South African Cochrane Centre,  
Medical Research Council (MRC)  
Cape Town, South Africa

Wale, Janet \*  
Cochrane Consumers Network (CCNet)  
Perth, Australia

Wieland, Susan  
United States Cochrane Center  
Brown University  
Providence, USA

Yaju, Yukari  
Medwatcher Japan  
Tokyo, Japan

Zwarenstein, Merrick  
Institute for Clinical Evaluative Sciences,  
Faculty of Medicine, University of Toronto and  
Sunnybrook and Women's College Health Sciences Centre  
Toronto, Canada

### ***Contributors***

All six authors participated in the October 2004 Ottawa brainstorming discussion, and worked via conference call and email to plan, build consensus, and write and revise the Ottawa Statement. Ottawa Group members contributed feedback on multiple drafts of the Statement. Karmela Krleža-Jerić, An-Wen Chan, and Kay Dickersin formed the core group that carried the planning, writing and editing process forward, with Karmela Krleža-Jerić taking the lead.

Karmela Krleža-Jerić initiated, conceptualized, organised and participated in the brainstorming meeting. She also contributed to conceptualizing and revising the Ottawa Statement, including the initial background document, coordinated the outreach and endorsement process, and contributed to the drafting and revising of the published article that accompanies the Statement.

An-Wen Chan contributed to organisation of the brainstorming meeting in which he also participated. He was a major contributor in the drafting and revising of the Ottawa Statement, including the initial background document, and the drafting and revising of the published article that accompanies the Statement.

Kay Dickersin contributed to conception, design and organisation of the brainstorming

meeting, in which she also participated. She prepared the first drafts of the Ottawa Statement, including the initial background document, and the published article, and contributed to their revisions. She also contributed to the outreach and endorsement process.

Jeremy Grimshaw contributed to the organisation of the brainstorming meeting, and chaired the meeting. He also contributed to the conceptualisation of the initial background document, revisions to the Ottawa Statement and the published article, and by reaching out to the scientific community.

Ida Sim contributed to revising of the background document for the brainstorming meeting, participated in the brainstorming discussion, and contributed to revising the Ottawa Statement and the published article.

Christian Gluud participated in the brainstorming discussion and subsequent revisions to the Statement and published article. He also contributed by reaching out and building a consensus around the Statement among European colleagues.

### ***Acknowledgments***

We thank Mark Bisby, and Isabelle Schmid, Canadian Institutes of Health Research - CIHR, as well as Kathie Clark, Co-Chair of the Canadian Coordinating Committee of the 12th Cochrane Colloquium (Ottawa) - Canadian Cochrane Centre, for their support of the Ottawa brainstorming meeting.

We thank David Moher, John Hoey, Doug Altman, Mike Clarke, Gerd Antes, David Bell, and Albert Clark for their helpful input into the preparation for the brainstorming meeting.

Finally, we would like to express our appreciation to Robbie Foy (Newcastle Univ.), Marie Hatem and Joanne Délage (Montreal Univ.), Genevieve Dubois-Flynn, Iranga Chikuru and Leanne Moussa (CIHR) for their invaluable recording contributions during the brainstorming meeting. Their comprehensive notes enabled us to incorporate the many important comments while editing the Ottawa Statement.